Lixte Net Debt To E B I T D A from 2010 to 2025
| LIXTW Stock | USD 0.03 0 2.86% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter 0.29079579 | Current Value 0.31 | Quarterly Volatility 1.7 K |
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 17.7 K, Other Operating Expenses of 2.7 M or Total Operating Expenses of 2.7 M, as well as many indicators such as Price To Sales Ratio of 56.09, Dividend Yield of 2.0E-4 or PTB Ratio of 5.8. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
Lixte | Net Debt To E B I T D A |
Latest Lixte Biotechnology's Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Lixte Biotechnology Holdings over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Lixte Biotechnology's Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Lixte Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | (111.66) | |
| Coefficient Of Variation | (1,483) | |
| Mean Deviation | 864.58 | |
| Median | 0.14 | |
| Standard Deviation | 1,656 | |
| Sample Variance | 2.7M | |
| Range | 8.3K | |
| R-Value | 0.1 | |
| Mean Square Error | 2.9M | |
| R-Squared | 0.01 | |
| Significance | 0.72 | |
| Slope | 33.28 | |
| Total Sum of Squares | 41.1M |
Lixte Net Debt To E B I T D A History
About Lixte Biotechnology Financial Statements
Lixte Biotechnology investors use historical fundamental indicators, such as Lixte Biotechnology's Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lixte Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | 0.29 | 0.31 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.